Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for
strategic studies evaluating the usefulness of including targeted therapeutics from the first
line with aflibercept +/- LV5FU2.